title: Targeted therapies: Afatinib--new therapy option for EGFR-mutant lung cancer.
authors: Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, Weill Cornell Medical College, 300 East 66th Street, New York, NY 10065, USA.
authors: Helena A
authors: HA
authors: Yu
authors: William
authors: W
authors: Pao
mesh_terms: D000077716:Afatinib; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000235:genetics; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics; D058990:Molecular Targeted Therapy; D009154:Mutation / Q000235:genetics*; D011799:Quinazolines / Q000627:therapeutic use*
chemical_list: D011799:Quinazolines; D000077716:Afatinib; C512478:EGFR protein, human; D066246:ErbB Receptors
references: N Engl J Med. 2005 Jul 14;353(2):123-32
references: 16014882
references: J Clin Oncol. 2013 Sep 20;31(27):3335-41
references: 23816963
references: Nat Rev Cancer. 2010 Nov;10(11):760-74
references: 20966921
references: Clin Cancer Res. 2013 Apr 15;19(8):2240-7
references: 23470965
references: Lancet Oncol. 2012 May;13(5):528-38
references: 22452896
references: J Clin Oncol. 2013 Sep 20;31(27):3342-50
references: 23816967
references: Lancet Oncol. 2012 Mar;13(3):239-46
references: 22285168
references: J Clin Oncol. 2013 Sep 20;31(27):3327-34
references: 23816960
references: Lancet Oncol. 2011 Aug;12(8):735-42
references: 21783417